BIONDVAX PHARMACEUTICALS LTD. INTERIM FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2021 NIS IN THOUSANDS UNAUDITED INDEX Page Balance Sheets F-2 - F-3 Statements of Comprehensive Loss F-4 Statements of Changes in Shareholder

BIONDVAX PHARMACEUTICALS LTD.

INTERIM FINANCIAL STATEMENTS

AS OF SEPTEMBER 30, 2021

- - - - - - - - - - -

BIONDVAX PHARMACEUTICALS LTD.

thousands, except share and per share data

The accompanying notes are an integral part of

the interim financial statements.

BIONDVAX PHARMACEUTICALS LTD.

thousands, except share and per share data

The accompanying notes

are an integral part of the interim financial statements.

BIONDVAX PHARMACEUTICALS LTD.

OF COMPREHENSIVE LOSS

thousands, except share and per share data

The accompanying notes are an integral part of

the interim financial statements.

BIONDVAX PHARMACEUTICALS LTD.

OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIENCY)

thousands, except share and per share data

The accompanying notes are an integral part of

the interim financial statements.

BIONDVAX PHARMACEUTICALS LTD.

OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIENCY)

thousands, except share and per share data

The accompanying notes are an integral part of

the interim financial statements.

BIONDVAX PHARMACEUTICALS LTD.

OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIENCY)

thousands, except share and per share data

The accompanying notes are an integral part of

the interim financial statements.

BIONDVAX PHARMACEUTICALS LTD.

thousands, except share and per share data

The accompanying notes are an integral part of

the interim financial statements

BIONDVAX PHARMACEUTICALS LTD.

thousands, except share and per share data

The accompanying notes are an integral part of

the interim financial statements.

BIONDVAX PHARMACEUTICALS LTD.

INTERIM FINANCIAL STATEMENTS

thousands, except share and per share data

the report date the Investment Center of the Ministry of Economy and Industry of the State of Israel has

yet to approve the grant to the company.

BIONDVAX PHARMACEUTICALS LTD.

NOTES TO INTERIM FINANCIAL STATEMENTS

thousands, except share and per share data

cautioned us that their letter is not a consent, agreement, amendment or waiver in respect of the terms of the Finance Contract, reserving

any other right or remedy the EIB may have now or subsequently. There is no guarantee that the decision by the EIB in their letter will

not change at any time and without any notice or that the EIB will not determine that an event of default has occurred under the Finance

Contract, which could result in all loans extended under the Finance Contract being accelerated and secured creditor remedies being exercised.

If some or all of the loans under the Finance Contract are accelerated by the EIB, or secured creditor remedies are exercised, we expect

such events to adversely impact our ability to continue as a going concern.

30, 2021, the EIB loan balance is $19,971 (approximately NIS 64,488).

has not generated any revenues and will need additional funds to finance its operations in the future.

Company intends to continue to finance its operating activities by raising capital. There are no assurances that the Company will be successful

in obtaining an adequate level of financing needed for its long-term research, development and potential commercialization activities.

not have the sufficient liquidity resources, the Company may not be able to continue the development of its prospective products or may

be required to implement a cost reduction and may be required to delay part of its development program. The Company's management

and Board of Directors are of the opinion that its current financial resources will be sufficient to continue the operations of the Company

for at least the next twelve months.

BIONDVAX PHARMACEUTICALS LTD.

FINANCIAL STATEMENTS

thousands, except share and per share data

2:- CONVENIENCE TRANSLATION INTO U.S. DOLLARS

The financial statements as of September

30, 2021 and for the nine months then ended have been translated into dollars using the representative exchange rate as of that date ($ 1 =

NIS 3.229). The translation was made solely for the convenience of the reader. The amounts presented in these financial statements should

not be construed to represent amounts receivable or payable in dollars or convertible into dollars, unless otherwise indicated in these

3: SIGNIFICANT ACCOUNTING POLICIES

These financial statements

have been prepared in a condensed format as of September 30, 2021, and for the three and nine months then ended ("interim financial

statements"). These financial statements should be read in conjunction with the Company's annual financial statements as of December

31, 2020, and for the year then ended and accompanying notes ("annual financial statements").

Basis of preparation of the interim

financial statements

The interim consolidated financial

statements have been prepared in accordance with generally accepted accounting principles for the preparation of financial statements

for interim periods, as prescribed in IAS 34, "Interim Financial Reporting", and in accordance with the disclosure requirements

of Chapter D of the Securities Regulations (Periodic and Immediate Reports), 1970.

The significant accounting

policies and methods of computation adopted in the preparation of the interim financial statements are consistent with those followed

in the preparation of the Company's annual financial statements.

NOTE 4: MAJOR EVENTS DURING THE PERIOD

BIONDVAX PHARMACEUTICALS LTD.

INTERIM FINANCIAL STATEMENTS

thousands, except share and per share data

NOTE 4: MAJOR EVENTS DURING THE PERIOD (cont.)